ONCOGENEX ANNOUNCES INITIATION OF PHASE 3 "AFFINITY" TRIAL FOR PATIENTS WITH ADVANCED PROSTATE CANCER

OncoGenex focuses on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.